Association of prostate volume with incidence and aggressiveness of prostate cancer

Figures & data

Figure 1 Distribution of PSA (A) and DRE- (B) and TRUS-determined (C) volumes among age groups.

Note: Cases with subsequently proven metastatic disease were excluded.
Abbreviations: DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.

Table 1 Clinical parameters of patients undergoing prostate biopsies

Parameters	40–54 years	55–69 years	70+ years	Total	P-value
Number of patients	58	271	113	442
Positive biopsies, n (%)	28 (48.28)	146 (53.87)	70 (61.90)	244 (55.20)	P<0.001
Mean Gleason score	6.57	6.71	6.86	6.74	P<0.025
Abnormal DREa	60%	64.40%	69.52%	65.76%
Mean DRE-estimated volume (mL)	32.04	36.99	41.51	37.46	P<0.05
Mean TRUS-determined volume (mL)	31.32	42.89	52.03	43.62	P<0.05
Mean PSA	8.91	14.05	19.45	11.78	P<0.05
Median PSA	5.4	6.2	7.3	6.3
Patients with a family history	28%	17.09%	16.13%	19.67%

Note:

a Abnormal DRE is defined as increased size of >30 g, nodules, or induration.

Abbreviations: DRE, digital rectal examination; PSA, prostate-specific antigen; TRUS, transrectal ultrasound.

Figure 2 Categorical breakdown by prostate volume.

Abbreviation: TRUS, transrectal ultrasound.

Table 2 Gleason scores by prostate volume

Parameters	Volume <35 cc	Volume >65 cc	P-value
Number of patients	166	66
Biopsy-positive patients, n (%)	110 (66.27)	27 (40.9)	P<0.001
Patients with Gleason score ≤7, n (%)	100 (90.9)	26 (96.29)	P<0.03
Patients with Gleason score ≥8, n (%)	10 (9.09)	1 (3.7)